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Single-inhaler fluticasone furoate/
umeclidinium/vilanterol versus fluticasone
furoate/vilanterol plus umeclidinium using
two inhalers for chronic obstructive
pulmonary disease: a randomized non-
inferiority study
Peter R. Bremner1, Ruby Birk2, Noushin Brealey2, Afisi S. Ismaila3,4, Chang-Qing Zhu2 and David A. Lipson5,6*
Abstract
Background: Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg has been
shown to improve lung function and health status, and reduce exacerbations, versus budesonide/formoterol in
patients with chronic obstructive pulmonary disease (COPD). We evaluated the non-inferiority of single-inhaler FF/
UMEC/VI versus FF/VI + UMEC using two inhalers.
Methods: Eligible patients with COPD (aged ≥40 years; ≥1 moderate/severe exacerbation in the 12 months before
screening) were randomized (1:1; stratified by the number of long-acting bronchodilators [0, 1 or 2] per day during
run-in) to receive 24-week FF/UMEC/VI 100/62.5/25 μg and placebo or FF/VI 100/25 μg + UMEC 62.5 μg; all
treatments/placebo were delivered using the ELLIPTA inhaler once-daily in the morning. Primary endpoint: change
from baseline in trough forced expiratory volume in 1 s (FEV1) at Week 24. The non-inferiority margin for the lower
95% confidence limit was set at − 50 mL.
Results: A total of 1055 patients (844 [80%] of whom were enrolled on combination maintenance therapy) were
randomized to receive FF/UMEC/VI (n = 527) or FF/VI + UMEC (n = 528). Mean change from baseline in trough FEV1
at Week 24 was 113 mL (95% CI 91, 135) for FF/UMEC/VI and 95 mL (95% CI 72, 117) for FF/VI + UMEC; the
between-treatment difference of 18 mL (95% CI -13, 50) confirmed FF/UMEC/VI’s was considered non-inferior to FF/
VI + UMEC. At Week 24, the proportion of responders based on St George’s Respiratory Questionnaire Total score
was 50% (FF/UMEC/VI) and 51% (FF/VI + UMEC); the proportion of responders based on the Transitional Dyspnea
Index focal score was similar (56% both groups). A similar proportion of patients experienced a moderate/severe
exacerbation in the FF/UMEC/VI (24%) and FF/VI + UMEC (27%) groups; the hazard ratio for time to first moderate/
severe exacerbation with FF/UMEC/VI versus FF/VI + UMEC was 0.87 (95% CI 0.68, 1.12). The incidence of adverse
events was comparable in both groups (48%); the incidence of serious adverse events was 10% (FF/UMEC/VI) and
11% (FF/VI + UMEC).
(Continued on next page)
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Conclusions: Single-inhaler triple therapy (FF/UMEC/VI) is non-inferior to two inhalers (FF/VI + UMEC) on trough
FEV1 change from baseline at 24 weeks. Results were similar on all other measures of efficacy, health-related quality
of life, and safety.
Trial registration: GSK study CTT200812; ClinicalTrials.gov NCT02729051 (submitted 31 March 2016).
Keywords: COPD, Exacerbations, FEV1, Lung function, Fluticasone furoate/umeclidinium/vilanterol, Randomized
controlled trial, Single-inhaler triple therapy
Background
The Global Initiative for Chronic Obstructive Lung Disease
(GOLD) strategy document recommends escalating to
combination triple therapy with a long-acting β2-agonist
(LABA), a long-acting muscarinic antagonist (LAMA) and
an inhaled corticosteroid (ICS) for patients with advanced
chronic obstructive pulmonary disease (COPD) and persist-
ent symptoms (GOLD Group D) who experience further
symptoms or exacerbations on dual LABA/LAMA or
LABA/ICS therapy [1]. Although triple therapy for COPD
using multiple inhalers is common in current clinical prac-
tice [2, 3], the comparative benefits of COPD treatment
regimens using single or multiple inhalers are not well
understood.
Triple therapy with a LAMA plus ICS/LABA adminis-
tered using multiple inhalers has been shown to improve
forced expiratory volume in 1 s (FEV1) and health status,
and reduce exacerbations and rescue medication use, in
patients with COPD compared with ICS plus LABA dual
therapy or LAMA monotherapy [4–9]. Several recent
large randomized controlled trials have also assessed the
efficacy and safety of triple ICS/LABA/LAMA therapy
using a single fixed-dose combination inhaler for patients
with COPD at increased exacerbation risk [10–12].
The FULFIL study demonstrated improvements in
trough FEV1, health status, and reductions in moderate/
severe exacerbation rate, with once-daily, single-inhaler
fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/
VI) versus twice-daily budesonide/formoterol (FOR)
[10]. Similarly, the TRILOGY study showed improve-
ments in lung function and exacerbation frequency with
a twice-daily, single-inhaler ICS/LABA/LAMA combin-
ation of beclomethasone dipropionate (BDP)/FOR/gly-
copyrronium bromide (GB) compared with BDP/FOR
alone [11]. Furthermore, results from the TRINITY
study confirmed that the twice-daily, single-inhaler
BDP/FOR/GB combination was non-inferior to twice-
daily BDP/FOR plus tiotropium using multiple inhalers
on change from baseline in pre-dose FEV1 [12].
Given that single-inhaler triple therapy is soon expected
to be widely available, the current study was specifically
designed to demonstrate the non-inferiority of the only
currently available once-daily, single-inhaler triple therapy
(FF/UMEC/VI) to an alternative once-daily triple therapy
regimen using two inhalers (FF/VI +UMEC) on trough
FEV1 after 24 weeks of treatment. To our knowledge, this
is the first study to specifically evaluate the same individual
component molecules administered using either a single
inhaler or multiple inhalers.
Methods
Study design
This was a phase III, 24-week, randomized, double-blind,
parallel group, multicenter non-inferiority study (GSK study
CTT200812; ClinicalTrials.gov identifier NCT02729051)
that assessed the efficacy of once-daily FF/UMEC/VI
100 μg/62.5 μg/25 μg using a single ELLIPTA inhaler
versus once-daily FF/VI 100 μg/25 μg plus UMEC 62.5 μg
using two ELLIPTA inhalers (Fig. 1). Prior to the beginning
of the 24-week treatment period, there was a 2-week run-in
period, during which patients continued their existing
COPD medications. At randomization following the run-in
period, all existing COPD medications were discontinued
and patients started their assigned study treatment, with
short-acting albuterol/salbutamol provided as rescue medi-
cation throughout the study. Study clinic visits occurred at
pre-screening (visit 0), screening (visit 1), randomization
(Week 0, visit 2), Week 4 (visit 3), Week 12 (visit 4), and
Week 24 (visit 5). A safety follow-up telephone contact or
clinic visit was conducted a week after study completion, or
in the event of an early withdrawal.
Patients
Patients aged ≥40 years with COPD and who were current/
former smokers with a ≥ 10-pack-year smoking history
were eligible for enrollment. Other key inclusion criteria in-
cluded: COPD Assessment Test™ (CAT) score ≥ 10 [13, 14];
a post-albuterol/salbutamol FEV1/forced vital capacity ratio
< 0.70; and a post-bronchodilator FEV1 < 50% of predicted
and ≥1 moderate/severe exacerbation in the previous
12 months or a post-bronchodilator FEV1 ≥ 50% to < 80%
of predicted and ≥2 moderate exacerbations or ≥1 severe
exacerbation requiring hospitalization in the previous
12 months.
Exclusion criteria included: a current diagnosis of asthma
(patients with a prior history of asthma were eligible if they
had a current diagnosis of COPD that was the primary cause
of their respiratory symptoms); α1-antitrypsin deficiency;
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active tuberculosis; other respiratory disorders that were the
primary cause of respiratory symptoms; lung resection sur-
gery in the previous 12 months; risk factors for pneumonia
(including immunosuppression and neurological disorders
affecting control of the upper airway [e.g. Parkinson’s disease
or myasthenia gravis]; pneumonia and/or moderate/severe
exacerbation that had not resolved at least 14 days prior to
screening; respiratory infections; abnormal findings on chest
X-ray; clinically significant comorbidities; unstable liver or
cardiac disease; and cancer. Patients with a high risk for
pneumonia (e.g. very low body mass index, severely mal-
nourished, or very low FEV1) were only to be included at
the discretion of the investigator.
All patients provided written, informed consent prior
to enrollment.
Treatments
Eligible patients were randomized (1:1) to receive 24 weeks
of FF/UMEC/VI 100 μg/62.5 μg/25 μg in a single inhaler
and placebo (second inhaler) or FF/VI 100 μg/25 μg and
UMEC 62.5 μg, in separate inhalers; all treatments/placebo
were delivered using the ELLIPTA inhaler once daily in the
morning. Randomization was stratified by the number of
long-acting bronchodilators (0, 1, or 2) per day during the
run-in.
Study assessments
The primary efficacy endpoint was change from baseline
in trough FEV1 at Week 24. Secondary efficacy end-
points included: proportion of responders based on the
St George’s Respiratory Questionnaire (SGRQ) Total
score at Week 24; change from baseline in SGRQ Total
score at Week 24; proportion of responders based on
Transitional Dyspnea Index (TDI) focal score at Week
24; TDI focal score at Week 24; and time to first moder-
ate/severe exacerbation. Safety endpoints included the
incidence of adverse events (AEs), serious AEs (SAEs),
and AEs of special interest (AESIs).
Spirometry was performed at screening and pre-dose at
each scheduled study visit during the treatment period
using standardized equipment according to American
Thoracic Society–European Respiratory Society guidelines
[15]. The SGRQ for COPD patients [16] was completed
by patients at randomization and Weeks 12 and 24. The
Baseline Dyspnea Index was measured at randomization
and the TDI was measured at Weeks 12 and 24; these as-
sessments were completed electronically by patients using
self-administered computerized versions. Potential COPD
exacerbations were identified based on patient-reported
symptoms in an eDiary and confirmed by follow-up with
the investigator. Exacerbations were defined as worsening
of COPD symptoms that were mild (self-managed by the
patient; corticosteroids or antibiotics were not required),
moderate (required oral/systemic corticosteroids and/or
antibiotics), or severe (required hospitalization). The
investigators and their study staff were responsible for
detecting, documenting, and reporting AEs at each study
visit. The CAT was completed at screening using the
eDiary, before any other assessments, to assess eligibility.
Statistical analyses
Sample size calculations used a one-sided 2.5% significance
level and an estimate of residual standard deviation (SD)
for trough FEV1 at Week 24 of 220 mL (the SD estimate
was based on previous phase III studies in patients with
COPD). A study with 816 evaluable patients for the
primary analysis would have 90% power to determine non-
inferiority of FF/UMEC/VI versus FF/VI +UMEC based on
trough FEV1 at Week 24, when the margin of non-
inferiority is 50 mL and the true mean treatment difference
is assumed to be 0 mL. It was estimated that ~ 20% of
patients who were randomized would either discontinue
Fig. 1 Study design
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study treatment or be excluded from the modified
per-protocol (mPP) population at Week 24, and so ~ 1020
patients were planned for randomization.
The intent-to-treat (ITT) population included all ran-
domized patients, except those randomized in error. The
mPP population included all patients in the ITT population
who did not have a protocol deviation affecting efficacy.
Data following a severe/moderate COPD exacerbation or
pneumonia were excluded from the analysis due to the
potential impact of the event or the medications used to
treat it. Patients with partial protocol deviations considered
to impact efficacy were included in the mPP population but
had their data excluded from analyses from the time of
deviation onwards.
The primary efficacy endpoint was analyzed for the
mPP population using a mixed model repeated measures
(MMRM) analysis, including trough FEV1 at Weeks 4,
12, and 24. The model included covariates of stratum
(number of long-acting bronchodilators per day during
the run-in [0/1 or 2]), baseline FEV1, visit, center group,
treatment, visit by baseline, and visit by treatment inter-
action. The non-inferiority margin was set at 50 mL (half
the minimal clinically important difference [MCID] for
trough FEV1 in COPD [17]. If the lower bound of the
two-sided 95% confidence interval (CI) around the FF/
UMEC/VI versus FF/VI + UMEC treatment difference
was above − 50 mL, then FF/UMEC/VI was considered
non-inferior to FF/VI + UMEC. The MMRM analysis
was repeated for the ITT population. All other end-
points were analyzed for the ITT population only.
The proportion of responders based on the SGRQ Total
score at Weeks 12 and 24 was analyzed using a generalized
linear mixed model, including covariates of baseline SGRQ
Total score, treatment group, number of long-acting bron-
chodilators per day during the run-in (0/1 or 2), geographic
region, visit, visit by baseline interaction, and visit by
treatment interaction. The number and proportion of
responders and non-responders for each treatment at
Weeks 12 and 24 was calculated and an odds ratio (OR) for
the comparison between FF/UMEC/VI and FF/VI +UMEC
with associated 95% CI was provided. The proportion of
responders based on the TDI focal score was analyzed in
the same way for proportion of responders based on SGRQ
Total score. Change from baseline in SGRQ Total score
and change from baseline in TDI total score at Weeks 12
and 24 were analyzed separately as described for the
primary analysis.
A Cox proportional hazards model was used to compare
the time to first moderate/severe COPD exacerbation
during 24 weeks of treatment with either FF/UMEC/VI or
FF/VI +UMEC. This model used covariates of treatment
group, gender, exacerbation history (0, 1, or 2 moderate/
severe exacerbations within 12 months of screening),
smoking status at screening, number of long-acting
bronchodilators per day during the run-in (0/1 or ≥2),
geographic region, and baseline percent predicted FEV1. A
Kaplan–Meier analysis was performed to produce a figure
showing Kaplan–Meier survivor functions of the propor-
tion of patients with a first moderate/severe exacerbation
over time for each treatment group.
The number and proportion of patients experiencing at
least one AE of any type, AEs within each body system,
and AEs within each Medical Dictionary for Regulatory
Activities preferred term were recorded for each treatment
group. Separate summaries were provided for all AEs,
drug-related AEs, fatal AEs, non-fatal SAEs, AESIs, and
AEs leading to withdrawal. SAEs and deaths were docu-
mented in case-narrative format.
Results
Patients
A total of 1311 patients were enrolled, of whom 1055 were
randomized to receive study treatment (ITT population;
FF/UMEC/VI, n = 527; FF/VI +UMEC, n = 528); 956 pa-
tients were included in the mPP population (FF/UMEC/VI,
n = 478; FF/VI +UMEC, n = 478). In the ITT population,
94% of patients completed the study in each treatment
group. Patient demographics and clinical characteristics in
the ITT population were generally well balanced between
the treatment groups, with no significant differences in
terms of disease severity, GOLD grade or exacerbation
history at baseline (Table 1); current and past medical con-
ditions and the incidence of cardiovascular risk factors at
baseline were also similar between the two treatment arms.
Patient characteristics in the mPP population were similar
(not shown).
Efficacy
In the mPP population, the mean change from baseline
in trough FEV1 at Week 24 was 113 mL (95% CI 91,
135) for FF/UMEC/VI and 95 mL (95% CI 72, 117) for
FF/VI + UMEC; the between-treatment difference was
18 mL (95% CI -13, 50) (Fig. 2). As the lower bound of
the 95% CI for the comparison was above the predefined
non-inferiority margin (− 50 mL), FF/UMEC/VI was
considered non-inferior to FF/VI + UMEC. Comparable
findings were observed in the ITT population: the mean
change from baseline in trough FEV1 at Week 24 was
107 mL (95% CI 87, 126) for FF/UMEC/VI and 81 mL
(95% CI 61, 100) for FF/VI + UMEC; the between-
treatment difference was 26 mL (95% CI -2, 53).
In the ITT population, the proportion of responders
based on the SGRQ Total score at Week 24 was similar
in the FF/UMEC/VI group (50%) and FF/VI + UMEC
group (51%); the OR of response versus non-response
for FF/UMEC/VI versus FF/VI + UMEC was 0.92 (95%
CI 0.71, 1.20). The mean change from baseline in SGRQ
Total score at Week 24 was − 5.8 (95% CI -7.0, − 4.7) for
Bremner et al. Respiratory Research  (2018) 19:19 Page 4 of 10
Table 1 Patient demographics and clinical characteristics (ITT population)
Characteristic FF/UMEC/VI 100/62.5/25 μg FF/VI 100/25 μg + UMEC 62.5 μg Total
(N = 527) (N = 528) (N = 1055)
Age (years), mean (SD) 66.7 (8.5) 65.9 (8.8) 66.3 (8.6)
Female, n (%) 136 (26) 134 (25) 270 (26)
Current smoker at screening, n (%) 209 (40) 192 (36) 401 (38)
Smoking pack-years, mean (SD) 43.4 (23.9) 44.2 (25.2) 43.8 (24.6)
Current cardiovascular risk factors, n (%) 379 (72) 367 (70) 746 (71)
Number of exacerbations in previous 12 months, n (%)a
1 moderate/severe 236 (45) 227 (43) 463 (44)
≥ 2 moderate/severe 291 (55) 301 (57) 592 (56)
≥ 2 moderate or ≥1 severe 352 (67) 360 (68) 712 (67)
History of pneumonia, n (%) 86 (16) 100 (19) 186 (18)
Screening lung function, mean (SD) n = 515 n = 512 n = 1027
Post-bronchodilator FEV1, mL 1247 (465) 1297 (471) 1272 (469)
Post-bronchodilator FVC, mL 2879 (885) 2896 (849) 2887 (867)
Post-bronchodilator FEV1/FVC ratio 0.440 (0.116) 0.455 (0.119) 0.447 (0.118)
Post-bronchodilator percent predicted FEV1 44.5 (14.5) 45.5 (14.1) 45.0 (14.3)
Percent reversibility 9.02 (11.22) 8.87 (10.15)b 8.95 (10.69)
Number of long-acting bronchodilators per day during the run-in, n (%)
0/1 225 (43) 226 (43) 451 (43)
2 302 (57) 302 (57) 604 (57)
Concomitant COPD medications taken at screening, n (%)
Single-inhaler maintenance bronchodilator 40 (8) 42 (8) 82 (8)
LAMA 32 (6) 35 (7) 67 (6)
LABA 8 (2) 7 (1) 15 (1)
Combination therapy 448 (85) 443 (84) 891 (84)
ICS + LABA+LAMA 198 (38) 193 (37) 391 (37)
ICS + LABA 144 (27) 137 (26) 281 (27)
LABA+LAMA 62 (12) 76 (14) 138 (13)
ICS + LABA+LAMA+ xanthine 29 (6) 25 (5) 54 (5)
ICS + LAMA 7 (1) 9 (2) 16 (2)
LABA+LAMA+xanthine 8 (2) 3 (< 1) 11 (1)
COPD severity at screening
GOLD grade, n (%) n = 515 n = 512 n = 1027
1 (mild) 0 1 (< 1) 1 (< 1)
2 (moderate) 174 (34) 189 (37) 363 (35)
3 (severe) 251 (49) 253 (49) 504 (49)
4 (very severe) 90 (17) 69 (13) 159 (15)
Reversible, n (%)c n = 515 n = 511 n = 1026
Yes 73 (14) 74 (14) 147 (14)
GOLD grade/exacerbation history, n (%)a n = 514 n = 512 n = 1026
Grade 1/2 with ≥2 moderate or ≥1 severe 173 (34) 190 (37) 363 (35)
Grade 3/4 with < 2 moderate and no severe 171 (33) 164 (32) 335 (33)
Grade 3/4 with ≥2 moderate or ≥1 severe 170 (33) 158 (31) 328 (32)
CAT score, mean (SD) 19.6 (5.8) 20.1 (6.1) 19.9 (6.0)
CAT COPD Assessment Test™, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s, FF fluticasone furoate, FVC forced vital capacity, GOLD
Global Initiative for Chronic Obstructive Lung Disease, ICS inhaled corticosteroid, ITT intent-to-treat, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist,
SD standard deviation, UMEC umeclidinium, VI vilanterol
aModerate exacerbations were defined as exacerbations requiring oral/systemic corticosteroids and/or antibiotics (not involving hospitalization). Severe exacerbations
were defined as exacerbations that required in-patient hospitalization
bFF/VI + UMEC, n = 511
cReversible was an increase in FEV1 of ≥12% and ≥200 mL following administration of salbutamol. Not reversible was an increase in FEV1 of < 200 or ≥200 mL increase
that is < 12% of the pre-salbutamol FEV1
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FF/UMEC/VI and − 4.9 (95% CI -6.1, − 3.8) for FF/VI +
UMEC; the between-treatment difference was − 0.9 (95%
CI -2.5, 0.7) (Fig. 3). The proportion of responders based
on TDI focal score at Week 24 was the same for FF/
UMEC/VI and FF/VI + UMEC (56% in each group; OR
of response versus non-response for FF/UMEC/VI
versus FF/VI + UMEC was 0.95 [95% CI 0.72, 1.25]). The
mean TDI focal score at Week 24 was 2.0 (95% CI 1.8,
2.3) for FF/UMEC/VI and 1.9 (95% CI 1.6, 2.1) for FF/
VI + UMEC; the between-treatment difference was 0.1
(95% CI -0.2, 0.5).
A similar proportion of patients (ITT population)
experienced a moderate/severe exacerbation in the FF/
UMEC/VI group (24%) and FF/VI + UMEC group (27%)
Fig. 2 Mean change from baseline in trough FEV1 over 24 weeks in a: the mPP population and b: the ITT population
Fig. 3 Mean change from baseline in SGRQ Total score over 24 weeks (ITT population)
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(Table 2). The hazard ratio for time to first on-treatment
moderate/severe exacerbation with FF/UMEC/VI versus
FF/VI + UMEC was 0.87 (95% CI 0.68, 1.12) (Fig. 4).
Safety
The proportion of patients who experienced at least one
AE was comparable between both treatment groups
(48%); the proportion of patients who had at least one
SAE was 10% in the FF/UMEC/VI group and 11% in the
FF/VI + UMEC group (Table 3). The most frequent AEs
were viral upper respiratory tract infection (FF/UMEC/
VI, 11%; FF/VI + UMEC, 10%), headache (6% in each
group), and COPD (FF/UMEC/VI, 4%; FF/VI + UMEC,
6%). The incidence of AESIs was similar between the
treatment groups, including pneumonia (FF/UMEC/VI,
3%; FF/VI + UMEC, 4%) and cardiovascular events (FF/
UMEC/VI, 6%; FF/VI + UMEC, 5%) (Table 3).
Discussion
This study aimed to evaluate an important clinical out-
come in patients with COPD following treatment with the
same three individual component molecules administered
using either a single inhaler or two inhalers. While this
appears to be scientifically self-evident, this was the first
study to specifically demonstrate non-inferiority of a
single-inhaler triple pharmacologic regimen to the same
treatments delivered using multiple inhalers.
This study showed that single-inhaler FF/UMEC/VI
100 μg/62.5 μg/25 μg is non-inferior to FF/VI 100 μg/
25 μg plus UMEC 62.5 μg using two inhalers based on
change from baseline in trough FEV1 at Week 24. The
non-inferiority margin for the lower 95% confidence
limit was set at − 50 mL, which is half the MCID for
trough FEV1 in COPD [17]. The proportions of
responders based on SGRQ Total score and TDI focal
score, and the time to first on-treatment moderate/severe
exacerbation, were similar between the treatment groups.
As expected, the incidence of AEs, SAEs, and AESIs was
comparable for FF/UMEC/VI and FF/VI + UMEC; the
incidence of pneumonia AESI was 3% and 4% for FF/
UMEC/VI and FF/VI +UMEC, respectively. These results
demonstrate that the efficacy and safety of single-inhaler
FF/UMEC/VI are similar to the same treatments delivered
using two inhalers in patients with COPD. Our findings
are supported by previous research, which showed that
the systemic exposure to FF, UMEC, and VI following
administration as a single-inhaler combination is similar
to that observed with the dual therapies FF/VI and
UMEC/VI [18].
The mean change from baseline in trough FEV1 at
Week 24 with FF/VI/UMEC in the ITT population in the
current study (107 mL) is lower than the change from
baseline reported with FF/UMEC/VI in the ITT popula-
tion in the FULFIL study at 24 weeks (142 mL) [10]. This
likely reflects the fact that 80% of the enrolled population
in the current study used dual, triple, or quadruple com-
bination therapies at baseline. Nevertheless, this reduced
level of improvement in lung function was associated with
a clinically meaningful improvement from baseline in
SGRQ Total score at Week 24 of − 5.8 units, which is
consistent with the − 6.6-unit change reported with FF/
UMEC/VI in the FULFIL study [10]. It should also be
noted that the mean improvement from baseline in trough
FEV1 at Week 24 with FF/VI/UMEC in the ITT popula-
tion in the current study was 26 mL (95% CI -2, 53)
greater than that observed with FF/VI + UMEC using two
inhalers. This indicates some potential for greater
consistency in the bronchodilator effect for the single-
inhaler combination across all patients, compared with
the two-inhaler regimen.
Our findings are also in line with a previous 52-week
study comparing twice-daily, single-inhaler BDP/FOR/
GB triple therapy with twice-daily BDP/FOR plus tiotro-
pium using multiple inhalers, which showed non-
inferiority for the single-inhaler formulation based on
change from baseline in pre-dose FEV1 (between-treat-
ment difference: − 3 mL [95% CI -33, 27]) [12]. The inci-
dence of AEs and SAEs with FF/UMEC/VI observed in
this study (48% and 10%, respectively) was higher than the
incidences observed with FF/UMEC/VI in the FULFIL
trial (39% and 5%, respectively). The current study was
designed to recruit a population with higher disease
burden and exacerbation risk, compared to the population
recruited to the FULFIL trial [10], which likely accounts
for the differences seen in adverse event reporting
between the two studies. These differences are therefore
not considered to be clinically relevant. The incidence of
pneumonia AESI in the FF/UMEC/VI group in the
current study was relatively low (3%) despite 16% of
Table 2 Summary of on-treatment COPD exacerbations
(ITT population)
F/UMEC/VI
100/62.5/25 μg
FF/VI 100/25 μg +
UMEC 62.5 μg
(N = 527) (N = 528)
Patients with a mild, moderate or
severe exacerbation, n (%)
134 (25) 145 (27)
Mild 8 (2) 5 (< 1)
Moderate 111 (21) 118 (22)
Severe 22 (4) 31 (6)
Moderate/Severe 129 (24) 142 (27)
Number of moderate/severe exacerbations, n (%)
0 398 (76) 386 (73)
1 105 (20) 111 (21)
≥ 2 24 (5) 31 (6)
COPD chronic obstructive pulmonary disease, FF fluticasone furoate, ITT
intent-to-treat, SD standard deviation, UMEC umeclidinium, VI vilanterol
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patients enrolled in this group having a history of
pneumonia.
A once-daily, single-inhaler treatment regimen offers a
simplified dosing option that may provide a number of
benefits to patients with COPD, such as reducing the
number of obligatory co-pays in markets where patients
are required to subsidize the cost of their medicines. A
single-inhaler regimen may also help to ensure that the
prescribed combination is delivered consistently and
reduce the risk of inhaler errors [19–21]. This may
improve patient adherence and outcomes, and reduce
associated healthcare costs. However, in the current
study, patients in both groups received their assigned
study treatment using double-dummy blind inhalers,
and so we were unable to directly assess the impact on
adherence of a simplified single-inhaler triple therapy
regimen versus the same treatments delivered using two
inhalers. Nevertheless, as numerical treatment differences
in favor of FF/VI/UMEC versus UMEC+FF/VI were con-
sistently observed in the ITT population for both mean
change from baseline in FEV1 and SGRQ total score, it is
possible that a more pragmatic, real-world efficacy study
might demonstrate such efficacy benefits.
Our results are specific to FF/UMEC/VI administered
using the ELLIPTA inhaler, so similar clinical findings
may not be observed when different molecules or inhaler
devices are combined. Another study limitation was the
lack of a control group receiving dual ICS/LABA or
LAMA/LABA therapy, although a dual therapy control
group was included in the FULFIL and forthcoming
IMPACT trials [10, 22]. A potential study strength
was that 80% of enrolled patients continued their
existing dual, triple or quadruple combination therapies
during the 2-week run-in period, and 67% continued to
remain at high risk of exacerbations. This meant that the
study population more closely resembled a real-world
COPD population who may benefit most from the
simplicity afforded by a once-daily, single-inhaler triple
therapy regimen.
Fig. 4 Time to first on-treatment moderate/severe exacerbation over the 24-week treatment period (ITT population)
Table 3 Overview of safety findings (ITT population)
Category, n (%) FF/UMEC/VI
100/62.5/25 μg
FF/VI 100/25 μg +
UMEC 62.5 μg
(N = 527) (N = 528)
On-treatment AEs 255 (48) 253 (48)
On-treatment drug-related AEs 27 (5) 19 (4)
On-treatment SAEs 52 (10) 57 (11)
On-treatment non-fatal SAEs 50 (9) 54 (10)
On-treatment fatal SAEs 4 (< 1) 4 (< 1)
On-treatment AESIsa
Adrenal suppression 1 (< 1) 0
Anticholinergic syndrome 12 (2) 5 (< 1)
Cardiovascular events 30 (6) 28 (5)
Cardiac arrhythmia 6 (1) 8 (2)
Cardiac failure 7 (1) 7 (1)
Ischemic heart disease 6 (1) 3 (< 1)
Hypertension 10 (2) 13 (2)
CNS hemorrhage/
cerebrovascular conditions
3 (< 1) 1 (< 1)
Decreased bone mineral
density and associated fractures
5 (< 1) 6 (1)
Hyperglycemia/new-onset
diabetes mellitus
7 (1) 6 (1)
Hypersensitivity 7 (1) 9 (2)
LRTI excluding pneumonia 16 (3) 11 (2)
Local steroid effects 12 (2) 14 (3)
Ocular effects 4 (< 1) 5 (< 1)
Pneumonia 14 (3) 21 (4)
Tremor 1 (< 1) 0
AE adverse event, AESI adverse event of special interest, CNS central nervous
system, FF fluticasone furoate, ITT intent-to-treat, LRTI lower respiratory tract
infection, SAE serious adverse event, SD standard deviation, UMEC umeclidinium,
VI vilanterol
aNo events were reported for the asthma/bronchospasm, effects on potassium,
gastrointestinal obstruction, or urinary retention AESI groups
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Conclusions
This study showed that single-inhaler FF/UMEC/VI
100 μg/62.5 μg/25 μg was non-inferior to FF/VI 100 μg/
25 μg plus UMEC 62.5 μg based on change from baseline
in trough FEV1 at Week 24 in patients with advanced
COPD. Our findings confirm that single-inhaler triple
therapy with FF/UMEC/VI offers similar efficacy, health-
related quality of life, and safety benefits as the same triple
therapy administered using two inhalers.
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